abstract |
The present invention relates to peptide biomarkers that are specifically recognized by autoantibodies present in the serum of rheumatoid arthritis (RA) patients. More specifically, the present invention uses PAD4 epitopes, BRAF epitopes and calpastatin epitopes, and these sequences for the diagnosis of RA, particularly for the diagnosis of RA in CCP-negative subjects. Methods and kits are provided. |